Just when it looked as though Teva Pharmaceuticals (TEVA) would settle at $10 in November 2017, the stock barely managed to hold the $11 mark and went on to more than double from there. But fourth-quarter results gave its shareholders a dose of reality. Revenue is in free-fall and the generic competition for Copaxone, which is earlier than expected, will hurt cash flow. This puts Teva’s management of its high debt at risk.
Copaxone and Generics Unit Under Pressure
Teva reported a 19.1% drop in Copaxone revenue and fourth-quarter revenue falling 15.9% Y/Y (to $3.114 billion). The Generics unit is especially disappointing as sales fell 16.2 percent. Teva’s $40 billion purchase of Allergan’s (AGN) Actavis generics business is now looking very foolish. The annualized price/sales multiple of 3.33 times will only go up for Actavis unit. Teva is under pressure to adjust downward product pricing for its unprofitable products to drive sales. It may need to discontinue products to cut its losses.


